93 related articles for article (PubMed ID: 10868311)
1. Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity.
Sturgill MG; Rashidbaigi A; Liao MJ; Zhao XX; Hua J; Trout R; Knill JR; Grasing KW
J Clin Pharmacol; 2000 Jun; 40(6):606-15. PubMed ID: 10868311
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
4. Serum interferon level and (2'-5')oligoadenylate synthetase activity in lymphocytes during clinical interferon application.
Lodemann E; Nitsche EM; Lang MH; Gerein V; Altmeyer P; Holzmann H; Kornhuber B
J Interferon Res; 1985; 5(4):621-8. PubMed ID: 2418131
[TBL] [Abstract][Full Text] [Related]
5. Determination of 2'-5'-oligoadenylate synthetase in serum and peripheral blood mononuclear cells before and after subcutaneous application of recombinant interferon beta and gamma.
Bruchelt G; Fierlbeck G; Schiebel U; Bogenschütz O; Rassner G; Niethammer D
Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):521-8. PubMed ID: 1457613
[TBL] [Abstract][Full Text] [Related]
6. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
7. Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B.
Shindo M; Okuno T; Matsumoto M; Takeda M; Takino T; Sokawa J; Iwata A; Sokawa Y
Hepatology; 1988; 8(2):366-70. PubMed ID: 2451634
[TBL] [Abstract][Full Text] [Related]
8. Interferon and 2',5'-oligo(A) synthetase activities in serum and blood mononuclear leukocytes of cattle after injection of bovine interferon-alpha 1.
Perino LJ; Short EC; Burge LJ; Winter DA; Fulton RW
Am J Vet Res; 1990 Jun; 51(6):886-92. PubMed ID: 1695068
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.
Osborn BL; Olsen HS; Nardelli B; Murray JH; Zhou JX; Garcia A; Moody G; Zaritskaya LS; Sung C
J Pharmacol Exp Ther; 2002 Nov; 303(2):540-8. PubMed ID: 12388634
[TBL] [Abstract][Full Text] [Related]
10. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.
Andreone P; Cursaro C; Gramenzi A; Buzzi A; Miniero R; Sprovieri G; Gasbarrini G
J Hepatol; 1994 Dec; 21(6):984-8. PubMed ID: 7699263
[TBL] [Abstract][Full Text] [Related]
11. Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha.
Merritt JA; Borden EC; Ball LA
J Interferon Res; 1985; 5(1):191-8. PubMed ID: 3989336
[TBL] [Abstract][Full Text] [Related]
12. [Clinical trials of recombinant gamma-interferon. Circulating interferon and the 2,5-oligoadenylate synthetase activity after intramuscular and inhalation administrations].
Sokolova TM; Lopatina OA; Nosik NN; Cheshik SG
Biull Eksp Biol Med; 1993 Jun; 115(6):633-4. PubMed ID: 7690616
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
[TBL] [Abstract][Full Text] [Related]
15. Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers.
Witter F; Barouki F; Griffin D; Nadler P; Woods A; Wood D; Lietman P
Clin Pharmacol Ther; 1987 Nov; 42(5):567-75. PubMed ID: 2445516
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.
Stürzebecher S; Maibauer R; Heuner A; Beckmann K; Aufdembrinke B
J Interferon Cytokine Res; 1999 Nov; 19(11):1257-64. PubMed ID: 10574618
[TBL] [Abstract][Full Text] [Related]
17. Serum 2',5'-oligoadenylate synthetase concentrations in acute and chronic hepatitis C.
Yang PM; Wang JT; Chiang BL; Lai MY; Chen DS
J Formos Med Assoc; 1997 May; 96(5):314-9. PubMed ID: 9170817
[TBL] [Abstract][Full Text] [Related]
18. Basis for dosing time-dependent changes in the antiviral activity of interferon-alpha in mice.
Ohdo S; Wang DS; Koyanagi S; Takane H; Inoue K; Aramaki H; Yukawa E; Higuchi S
J Pharmacol Exp Ther; 2000 Aug; 294(2):488-93. PubMed ID: 10900223
[TBL] [Abstract][Full Text] [Related]
19. Decreased Epstein-Barr virus-induced transformation, and elevated 2-5A synthetase and RNase L activity in peripheral blood mononuclear cells from patients treated with recombinant interferon alfa 2b.
Fronko GE; Suhadolnik RJ; Vonderheid EC; Karikó K; Reichenbach NL; Chavin KD; Henderson EE
Biochem Biophys Res Commun; 1988 May; 153(1):448-53. PubMed ID: 2837212
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of interferon treatment in patients with renal cell carcinoma and bladder carcinoma by oligo-A synthetase assay and determination of immunological parameters.
Grups JW; Komprecht B
J Biol Regul Homeost Agents; 1989; 3(3):98-101. PubMed ID: 2516404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
